Duke-NUS Gastric Cancer Precursors Research: Mutational Signatures and Clonal Hematopoiesis Reveal Key Drivers

Breakthrough Insights from Duke-NUS: Unraveling Gastric Cancer Precursors

The latest research from Duke-NUS Medical School in Singapore has illuminated critical mechanisms driving the progression from intestinal metaplasia (IM)—a precancerous condition where stomach lining cells transform into intestine-like cells—to gastric cancer, one of Asia's deadliest malignancies. Published in Cancer Discovery on March 2, 2026, the study titled "Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence" analyzed over 1,500 IM samples from six countries, including Singapore, South Korea, Japan, Hong Kong, the US, and Taiwan. Led by researchers like Kie Kyon Huang and Patrick Tan from Duke-NUS's Program in Cancer and Stem Cell Biology, this work under the Singapore Gastric Cancer Consortium reveals how age, smoking, genetic mutations, and microbial shifts converge to heighten risk.

Gastric cancer, also known as stomach cancer, claims around 300 lives annually in Singapore, ranking among the top 10 cancer-related deaths despite being the sixth most common cancer with approximately 1,000 new cases yearly. Globally, it causes over 769,000 deaths yearly, with higher incidence in East Asia due to factors like Helicobacter pylori (Hp) infection, which drives 75% of cases through chronic inflammation. In Singapore, late-stage diagnoses (over 60% at stages III-IV) underscore the need for better precursors detection, where five-year survival drops sharply.

What is Intestinal Metaplasia and Why Does It Matter?

Intestinal metaplasia represents a key step in the Correa cascade—the pathological sequence from gastritis to gastric cancer. Normally, the stomach's glandular epithelium secretes acid and enzymes; in IM, chronic irritation (often Hp-induced) prompts cells to mimic intestinal goblet cells, producing mucin. This reversible-yet-risky change elevates cancer odds by 3-6 times, though annual progression risk remains low (0.18-0.25%). Risk amplifiers include incomplete IM subtype, extensive spread (OLGIM stages II-IV), family history, and ethnicity—Chinese Singaporeans face higher rates.

Clinicians struggle to predict which IM patients progress, prompting the Duke-NUS team's multi-omics approach: high-depth targeted sequencing (1,108x average) of 277 cancer-related genes, whole-genome sequencing (WGS), RNA-seq, single-cell RNA-seq, DNA methylation, organoid models, and microbiome profiling.

Key Mutational Drivers Identified in IM Cells

The study pinpointed 47 significantly mutated genes in IM, 25 novel, spanning chromatin remodeling (ARID1A, ARID2), Wnt signaling (FBXW7), TGF-β (SMAD3), and MAPK (KRAS G12D, BRAF D594G, MAP2K1 F53L). ARID1A truncations—seen in 17-27% of gastric cancers—boosted early gastric neoplasia (EGN) odds 6.2-fold (P=1.5×10⁻³), acting as a growth suppressor. KRAS/MAPK alterations upregulated ERK signaling (NES=2.4), validated in organoids where pyrvinium (an antiparasitic) selectively killed IM cells (P<0.0005), hinting at repurposed therapies.

• ARID1A: High-risk driver, poor prognosis.
• KRAS/BRAF/MAP2K1: MAPK hyperactivation, druggable.
• PIGR: Truncations impair mucosal immunity, co-occur with CH.

Higher mutation burdens in high-incidence regions (Japan/Korea median 28.5 vs. Singapore/China 20; P=4.1×10⁻¹¹) correlated with Hp prevalence (South Korea 22.6% vs. Singapore 1.4%).

SBS17: The IM-Specific Mutational Signature

WGS on 20 IMs uncovered SBS17—a signature absent in normal gastric tissue but prevalent in 26.2% of antral IMs (1.57-fold higher in high-risk countries, P=8.5×10⁻⁶). Linked to late-replication timing (14.5x enrichment), hypomethylation, tobacco (P=6.2×10⁻³), and oxidative stress (elevated 8-oxo-dG), SBS17 ties to OXPHOS dysregulation, fueling IM persistence.

This signature stratifies risk, aiding precision screening.

Clonal Hematopoiesis: A Novel Non-Epithelial Risk Factor

Clonal hematopoiesis (CH)—age-related blood stem cell mutations (DNMT3A R882, TET2, ASXL1)—prevailed in 21.1% of 1,067 IM patients, versus lower in controls. High CH (VAF>5%) independently predicted dysplasia/EGN (P=6.4×10⁻³), with smokers overrepresented (ASXL1 P=1.7×10⁻⁴). CH co-occurred with PIGR loss (OR=2.8), boosting IgA plasma cells, T cells, and oral bacteria like Streptococcus (P=8.2×10⁻³).

FISH/Stereo-seq confirmed oral pathogens colonizing IM, suggesting CH impairs immunity, promoting progression. Prof. Patrick Tan notes: "Risk builds through ageing, genetics, immune shifts, and bacteria."

Microbial Shifts and Immune Dysregulation in High-Risk IM

Shotgun metagenomics revealed oral-derived bacteria enrichment in CH-high IM, with Streptococcus anginosus inflaming tissues. PIGR mutations hindered IgA secretion, altering microbiota. Hp CagA variants (e.g., East Asian-specific) modulated ASPP2 binding, varying virulence by region.

These insights advocate periodontal health checks for at-risk patients.

Singapore's Gastric Cancer Burden and Screening Challenges

Singapore's age-standardized incidence (15-20/100,000) exceeds Western rates, driven by Chinese ethnicity, Hp, smoking, and diet. Over 60% late diagnoses yield poor survival; the Consortium's 2007 longitudinal study pushes early endoscopy for high-risk (family history, IM).

• ~1,000 new cases/year.
• 300-500 deaths/year.
• Men 2x higher risk; peaks 60-70s.

Prof. Yeoh Khay Guan: "Find the right people... with interventions before cancer strikes."

Therapeutic Horizons: From Organoids to Clinical Trials

Organoids validated MAPK inhibitors (ulixertinib) and pyrvinium, reducing IM viability. Risk models (AUC 0.773) integrate genomics, CH, OLGIM for surveillance. Future: Blood tests for CH/SBS17, antibiotics for oral bugs, ARID1A-targeted drugs.

Duke-NUS: Powering Singapore's Biomedical Research Excellence

Duke-NUS, a National University of Singapore graduate school, excels in precision oncology. Patrick Tan, Senior Vice-Dean (Research), leads PRECISE and NPM, fostering multi-institutional consortia. This study exemplifies Singapore's RIE2025 investments in healthy longevity.Explore research jobs at Singapore universities

Career Opportunities in Cancer Genomics Research

Such breakthroughs demand bioinformaticians, geneticists, clinicians. Duke-NUS offers PhD/postdoc roles in CSCB; Singapore's ecosystem (A*STAR, NUHS) attracts global talent. Skills: NGS analysis, organoid culture, AI modeling.Tips for academic CVs Rate professors

Future Outlook: Precision Prevention for Gastric Cancer

Integrating CH biomarkers, microbial profiling, and lifestyle mods could slash incidence 40% via prevention. Trials for pyrvinium, vaccines loom. For researchers eyeing Singapore higher ed jobs, Duke-NUS exemplifies impactful science. Engage via higher-ed-jobs, university-jobs, career advice.

Photo by Andy Wang on Unsplash